Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The Effect of Mitapivat on Cerebral Perfusion and Oxygen Metabolism in Sickle Cell Disease
2024-513528-41-02Phase 3Authorised
- Sponsor
- Amsterdam University Medical Center
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of mitapivat in sickle cell disease (SCD) and sickle cell anemia (SCA), sponsored by Amsterdam University Medical Center. Planned start Jun 2025; status: authorised.
02
Drugs
mitapivat
03
Conditions
sickle cell disease (SCD)sickle cell anemia (SCA)
Beyond the preview
Go deeper on 2024-513528-41-02.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513528-41-02.